About Dolichol-phosphate mannosyltransferase subunit 1
Dolichol-phosphate mannosyltransferase subunit 1 (DPM1) is a protein
from Homo sapiens identified by UniProt accession
O60762, 260 residues long.
MolForge cross-references it against 0 known binders and
43 disease associations.
Target properties
| Protein name | Dolichol-phosphate mannosyltransferase subunit 1 |
|---|
| UniProt accession | O60762 |
|---|
| Gene | DPM1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 260 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (43)
Diseases linked to this target (Open Targets).
- congenital disorder of glycosylation type 1E · score 0.80
- DPM1-CDG · score 0.76
- SRD5A3-congenital disorder of glycosylation · score 0.55
- congenital disorder of glycosylation type I · score 0.50
- neurodegenerative disease · score 0.50
- genetic disorder · score 0.41
- congenital disorder of glycosylation · score 0.12
- hepatocellular carcinoma · score 0.06
- bipolar disorder · score 0.05
- body fat percentage · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60762-F1 | alphafold | PREDICTED | 88.55 | — |
Amino-acid sequence (260 residues)
MASLEVSRSP RRSRRELEVR SPRQNKYSVL LPTYNERENL PLIVWLLVKS FSESGINYEI IIIDDGSPDG TRDVAEQLEK IYGSDRILLR PREKKLGLGT AYIHGMKHAT GNYIIIMDAD LSHHPKFIPE FIRKQKEGNF DIVSGTRYKG NGGVYGWDLK RKIISRGANF LTQILLRPGA SDLTGSFRLY RKEVLEKLIE KCVSKGYVFQ MEMIVRARQL NYTIGEVPIS FVDRVYGESK LGGNEIVSFL KGLLTLFATT
Explore Dolichol-phosphate mannosyltransferase subunit 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets